Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
TRML Stock Forecast 2026-2027
$47.98
Current Price
$1.23B
Market Cap
Buy 1
Hold 7
Sell 0
Wall St Analyst Ratings
Distance to TRML Price Targets
+0.0%
To High Target of $48.00
+0.0%
To Median Target of $48.00
+0.0%
To Low Target of $48.00
TRML Price Momentum
0.0%
1 Week Change
0.0%
1 Month Change
+217.7%
1 Year Change
0.0%
Year-to-Date Change
-0.6%
From 52W High of $48.27
+315.1%
From 52W Low of $11.56
📊 TOP ANALYST CALLS
Did TRML Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if Tourmaline Bio is one of their latest high-conviction picks.
Latest TRML Stock Price Targets & Analyst Predictions
Based on our analysis of 16 Wall Street analysts, TRML has a neutral consensus with a median price target of $48.00 (ranging from $48.00 to $48.00). The overall analyst rating is N/A (N/A/10). Currently trading at $47.98, the median forecast implies a 0.0% upside. This outlook is supported by 1 Buy, 7 Hold, and 0 Sell ratings.
The most optimistic forecast comes from Kostas Biliouris at BMO Capital, projecting a 0.0% upside. Conversely, the most conservative target is provided by Kostas Biliouris at BMO Capital, suggesting a 0.0% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
TRML Analyst Ratings
1
Buy
7
Hold
0
Sell
TRML Price Target Range
Low
$48.00
Average
$48.00
High
$48.00
Current: $47.98
Latest TRML Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for TRML.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Sep 15, 2025 | BMO Capital | Kostas Biliouris | Market Perform | Downgrade | $48.00 |
| Sep 11, 2025 | Piper Sandler | Yasmeen Rahimi | Neutral | Downgrade | $48.00 |
| Sep 10, 2025 | Truist Securities | Robyn Karnauskas | Hold | Downgrade | $48.00 |
| Sep 10, 2025 | Chardan Capital | Daniil Gataulin | Neutral | Downgrade | $48.00 |
| Sep 10, 2025 | Guggenheim | Yatin Suneja | Neutral | Downgrade | $48.00 |
| Sep 10, 2025 | HC Wainwright & Co. | Yi Chen | Neutral | Downgrade | $48.00 |
| Sep 9, 2025 | Jefferies | Roger Song | Hold | Downgrade | $47.50 |
| Sep 9, 2025 | Wedbush | Laura Chico | Neutral | Downgrade | $48.00 |
| Sep 9, 2025 | LifeSci Capital | Rami Katkhuda | Market Perform | Downgrade | $48.00 |
| Aug 14, 2025 | Guggenheim | Yatin Suneja | Buy | Reiterates | $55.00 |
| Aug 14, 2025 | Chardan Capital | Daniil Gataulin | Buy | Maintains | $70.00 |
| May 5, 2025 | HC Wainwright & Co. | Yi Chen | Buy | Reiterates | $50.00 |
| May 5, 2025 | Chardan Capital | Daniil Gataulin | Buy | Maintains | $70.00 |
| Apr 23, 2025 | Chardan Capital | Daniil Gataulin | Buy | Initiates | $70.00 |
| Mar 14, 2025 | Wedbush | Laura Chico | Outperform | Maintains | $43.00 |
| Mar 14, 2025 | HC Wainwright & Co. | Yi Chen | Buy | Maintains | $50.00 |
| Mar 6, 2025 | Wedbush | Laura Chico | Outperform | Initiates | $42.00 |
| Feb 24, 2025 | LifeSci Capital | Jimmy Shan | Outperform | Initiates | $58.00 |
| Dec 11, 2024 | Cantor Fitzgerald | Josh Schimmer | Overweight | Reiterates | $25.00 |
| Dec 11, 2024 | HC Wainwright & Co. | Yi Chen | Buy | Reiterates | $49.00 |
Tourmaline Bio Inc. (TRML) Competitors
The following stocks are similar to Tourmaline Bio based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
TRML
Tourmaline Bio
mkt cap
1.23B
Tourmaline Bio Inc. (TRML) Financial Data
Tourmaline Bio Inc. has a market capitalization of $1.23B with a P/E ratio of -16.6x. The company generates $0 in trailing twelve-month revenue with a 0.0% profit margin.
Revenue growth is N/A quarter-over-quarter, while maintaining an operating margin of 0.0% and return on equity of -29.6%.
Valuation Metrics
Market Cap
$1.23B
Enterprise Value
$993.63M
P/E Ratio
-16.6x
PEG Ratio
-0.5x
Price/Sales
N/A
Growth & Margins
Revenue Growth (YoY)
N/A
Gross Margin
N/A
Operating Margin
0.0%
Net Margin
0.0%
EPS Growth
N/A
Financial Health
Cash/Price Ratio
+19.4%
Current Ratio
24.7x
Debt/Equity
0.1x
ROE
-29.6%
ROA
-20.9%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
Tourmaline Bio Inc. (TRML) Business Model
About Tourmaline Bio Inc.
What They Do
Develops therapies for immune-inflammatory diseases.
Business Model
Tourmaline Bio Inc. generates revenue by advancing its pipeline of innovative therapeutic candidates through clinical trials aimed at treating immune-inflammatory diseases. The company focuses on addressing significant unmet medical needs, which not only positions it as a leader in biotechnology but also enhances its potential for successful commercialization of its therapies.
Additional Information
With a commitment to scientific excellence and strategic partnerships, Tourmaline Bio is poised to significantly impact the healthcare market. Its focus on personalized and targeted medicine aligns with the industry's shift towards biologics, suggesting strong growth potential in the evolving pharmaceutical landscape.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
76
CEO
Dr. Sandeep C. Kulkarni M.D.
Country
United States
IPO Year
2023
Website
www.tourmalinebio.comTourmaline Bio Inc. (TRML) Latest News & Analysis
Latest News
Quick Summary
Novartis' tender offer to acquire all outstanding shares of Tourmaline Bio, Inc. at $48.00 per share expired on October 27, 2025.
Why It Matters
Novartis's acquisition of Tourmaline Bio at $48 per share may impact its stock price, investor sentiment, and future growth prospects, signaling strategic expansion in biotech.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Novartis completes acquisition of Tourmaline Bio
6 months ago
Quick Summary
Novartis has completed its acquisition of Tourmaline Bio, Inc., which is now an indirect wholly owned subsidiary. Tourmaline shares have ceased trading on Nasdaq.
Why It Matters
Novartis acquiring Tourmaline Bio enhances its portfolio and growth potential, impacting market positioning and future revenue streams, influencing investor confidence and stock performance.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Novartis announces expiration of Hart-Scott-Rodino waiting period of Tourmaline Bio tender offer
6 months ago
Quick Summary
Novartis' tender offer to acquire Tourmaline Bio at $48 per share has cleared the HSR Act waiting period. The offer expires on October 27, 2025, unless extended or terminated.
Why It Matters
The expiration of the HSR Act waiting period signals progress in Novartis' acquisition of Tourmaline Bio, potentially enhancing Novartis' portfolio and affecting stock valuations.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Kahn Swick & Foti is investigating the proposed $48 per share cash sale of Tourmaline Bio, Inc. to Novartis AG to assess the adequacy of the offer and the sale process.
Why It Matters
The investigation into Tourmaline Bio's sale to Novartis could affect the stock's price and investors' returns, depending on the adequacy of the proposed cash offer.
Source: Business Wire
Market Sentiment:
Neutral
Quick Summary
Novartis has initiated a tender offer to acquire all shares of Tourmaline Bio at $48 per share in cash. This follows a merger agreement announced on September 8, 2025.
Why It Matters
The acquisition of Tourmaline Bio by Novartis at $48 per share indicates a strategic expansion, potentially boosting Novartis' market position and future earnings, impacting stock performance and investor sentiment.
Source: GlobeNewsWire
Market Sentiment:
Neutral
SHAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Tourmaline Bio, Inc. (NASDAQ: TRML)
7 months ago
Quick Summary
Juan Monteverde's firm, Monteverde & Associates PC, has achieved recognition as a Top 50 Class Action Firm in 2024 and has secured millions for shareholders.
Why It Matters
The recognition of Monteverde & Associates highlights the effectiveness of class action lawsuits in protecting shareholder interests, potentially influencing investor confidence and market perceptions.
Source: PRNewsWire
Market Sentiment:
Neutral
Frequently Asked Questions About TRML Stock
What is Tourmaline Bio Inc.'s (TRML) stock forecast for 2026?
Based on our analysis of 16 Wall Street analysts, Tourmaline Bio Inc. (TRML) has a median price target of $48.00. The highest price target is $48.00 and the lowest is $48.00.
Is TRML stock a good investment in 2026?
According to current analyst ratings, TRML has 1 Buy ratings, 7 Hold ratings, and 0 Sell ratings. The stock is currently trading at $47.98. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for TRML stock?
Wall Street analysts predict TRML stock could reach $48.00 in the next 12 months. This represents a 0.0% increase from the current price of $47.98. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Tourmaline Bio Inc.'s business model?
Tourmaline Bio Inc. generates revenue by advancing its pipeline of innovative therapeutic candidates through clinical trials aimed at treating immune-inflammatory diseases. The company focuses on addressing significant unmet medical needs, which not only positions it as a leader in biotechnology but also enhances its potential for successful commercialization of its therapies.
What is the highest forecasted price for TRML Tourmaline Bio Inc.?
The highest price target for TRML is $48.00 from Kostas Biliouris at BMO Capital, which represents a 0.0% increase from the current price of $47.98.
What is the lowest forecasted price for TRML Tourmaline Bio Inc.?
The lowest price target for TRML is $48.00 from Kostas Biliouris at BMO Capital, which represents a 0.0% increase from the current price of $47.98.
What is the overall TRML consensus from analysts for Tourmaline Bio Inc.?
The overall analyst consensus for TRML is neutral. Out of 16 Wall Street analysts, 1 rate it as Buy, 7 as Hold, and 0 as Sell, with a median price target of $48.00.
How accurate are TRML stock price projections?
Stock price projections, including those for Tourmaline Bio Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: May 10, 2026 3:52 PM UTC